Core Viewpoint - BioStem Technologies, Inc. is progressing towards a Nasdaq uplisting by filing its audited consolidated financial statements for the fiscal years ended December 31, 2024, and 2025, marking a significant milestone for the company [1][2]. Financial Progress - The company has published its audited financial statements for 2024 and 2025, which is a crucial step in establishing robust financial reporting processes [2]. - The appointment of a new CFO, auditor, and audit committee chair further emphasizes the company's commitment to improving its financial governance [2]. Corporate Strategy - Listing on Nasdaq is a top priority for BioStem, as it would enhance visibility, improve stock liquidity, provide a more accurate market valuation, and attract top talent [2]. - The company is focused on advancing its corporate initiatives, including the development and commercialization of perinatal tissue allograft products [1][2]. Quality Assurance - BioStem's quality management system and standard operating procedures have been accredited by the American Association of Tissue Banks (AATB), ensuring compliance with current Good Tissue Practices (cGTP) and Good Manufacturing Processes (cGMP) [3]. - The company offers a portfolio of quality brands, including Neox, Clarix, VENDAJE, and American Amnion™ [3]. Company Overview - BioStem Technologies is a publicly traded biomedical innovator specializing in advanced allograft solutions derived from perinatal tissue, utilizing proprietary technologies like BioRetain, CryoTek, and SteriTek [2]. - The company is committed to advancing innovation in regenerative medicine with a growing portfolio of products and expanding clinical research initiatives [2].

Core Insights - BioStem Technologies, Inc. reported a significant decline in revenue for Q4 2025, with net revenue of $10.1 million, a 55% decrease compared to Q4 2024, primarily due to reimbursement uncertainty and competitive pressures [5][6] - The company completed the acquisition of BioTissue Holdings Inc. in January 2026, which is expected to enhance its product portfolio and commercial reach [9][10] - BioStem anticipates first quarter 2026 revenue to be between $5 million and $6 million, with expectations for growth in the hospital business in the second half of the year [12] Recent Financial and Business Highlights - CEO Jason Matuszewski emphasized the company's strengthened position and diversification following the BioTissue acquisition, which expands its market presence [3] - The gross profit margin for Q4 2025 was 97%, up from 84% in Q4 2024, attributed to a shift in product mix [5] - Operating expenses increased to $17.3 million in Q4 2025 from $10.7 million in Q4 2024, largely due to charges for potentially uncollectible accounts receivable [6] Financial Results Overview - For the full year 2025, net revenue was $47.5 million, down from $69.7 million in 2024, driven by lower wound care volume [8] - Gross profit for 2025 was $44.4 million, or 94% of net revenue, compared to $55.9 million or 80% in 2024 [10] - The company reported a GAAP net loss of $6.6 million for 2025, a significant decline from a net income of $31 million in 2024 [11] Cash Position and Future Outlook - As of December 31, 2025, cash equivalents totaled $29.5 million, which decreased to approximately $16 million post-BioTissue acquisition [7] - The company expects to drive sequential and year-over-year growth in the hospital business after integrating the BioTissue assets and expanding its salesforce [12]

Core Viewpoint - BioStem Technologies, Inc. will release its fourth quarter and full year 2025 financial results on March 24, 2026, and will host a conference call and webcast at 4:30 PM ET [1]. Group 1: Company Overview - BioStem Technologies is a leading MedTech company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products for regenerative medicine [1][3]. - The company utilizes a proprietary BioRetain processing method, which is designed to maintain growth factors and preserve tissue structure [3]. - BioStem's quality management system has been accredited by the American Association of Tissue Banks and complies with current Good Tissue Practices and Good Manufacturing Processes [3]. Group 2: Upcoming Events - The upcoming conference call and webcast will feature an overview of the quarter presented by CEO Jason Matuszewski and CFO Brandon Poe [2]. - Registration for the event is available through a provided link [2]. Group 3: Contact Information - For further inquiries, BioStem can be contacted via their website, email, or social media platforms [5].

Summary of BioStem Technologies Conference Call Company Overview - **Company**: BioStem Technologies - **Industry**: Regenerative Medicine, Wound Care - **CEO**: Jason Matuszewski - **Conference**: 46th Annual TD Cowen Healthcare Conference Core Points and Arguments - **Mission**: BioStem aims to create and deliver advanced wound healing technologies, addressing the significant challenges posed by chronic and acute wounds, which have an estimated economic impact of over $30 billion annually in the U.S. [2][4] - **Key Pillars**: The company is built on three pillars: differentiated technology, strong operational and clinical foundation, and a scalable growth engine [3] - **Technologies**: BioStem's technology platform includes BioREtain, CryoTek, and SteriTek, with a focus on perinatal-derived allograft brands like Neox and Clarix [3] - **Intellectual Property**: The company holds 58 issued U.S. patents and 68 pending patents, showcasing a strong IP portfolio [3] - **Market Opportunity**: BioStem targets a multi-billion dollar market, with a soft tissue allograft opportunity exceeding $23 billion across six core segments: orthopedics, chronic wound care, foot and ankle, urology, spine, and women's health [5] Financial Performance - **Revenue**: In 2025, the surgical revenue generated approximately $29 million, largely unaffected by CMS's wound pricing changes [6] - **EBITDA**: The BioTissue surgical and wound care assets delivered a single-digit positive EBITDA in 2025 [17] - **Cash Position**: The company has around $16 million in cash on the balance sheet, indicating a strong position for future investments [18] Market Dynamics - **Reimbursement Changes**: The transition from a bundled payment system to a fixed rate per square centimeter allows for treatment of larger wounds, which is expected to enhance market access [12][13] - **Challenges**: There are concerns regarding access to products in physician offices and mobile wound care settings due to the new reimbursement rates [27][28] - **Regulatory Environment**: The company is focused on generating clinical evidence to support reimbursement and market access, particularly in light of changing LCDs and payment methodologies [29] Strategic Initiatives - **Acquisition Impact**: The acquisition of BioTissue has expanded BioStem's product offerings and market reach, with a focus on diversifying the portfolio and driving growth [5][10] - **Sales Expansion**: The company has increased its sales force with 18 direct representatives and over 30 independent agents, aiming to penetrate new markets and enhance distribution [20] - **Future Products**: BioStem is looking forward to a 510(k) product launch in the middle to back half of the year, which will further diversify its offerings [4][19] Leadership and Management - **Management Team**: The company has assembled a leadership team with extensive experience in clinical research, commercial education, manufacturing, regulatory, and finance [16] - **New Appointments**: Barry Hassett has been appointed as Chief Commercial Officer, and Lita Lilly as VP of Sales, both bringing valuable experience from BioTissue [17] Conclusion - **Long-term Vision**: BioStem is positioned to capitalize on opportunities in regenerative medicine, leveraging its platform of perinatal tissues and focusing on evidence-based approaches to support its growth strategy [21]

Core Insights - BioStem Technologies, Inc. emphasizes the importance of the FDA's recent openness to Bayesian statistical methodologies in clinical trial design, which could enhance the efficiency and effectiveness of clinical studies in wound care [1][2][6] Group 1: FDA's Evolving Stance - FDA Commissioner Dr. Martin Makary described the agency's evolving stance on Bayesian approaches as a "leap forward" for clinical science, highlighting their potential to improve trial design and data integration [2] - The FDA's shift aligns with emerging regulatory guidance on Bayesian methods, indicating a more flexible approach to clinical trial methodologies [2] Group 2: BioStem's Clinical Research - BioStem's recent peer-reviewed randomized controlled trial demonstrated that BioRetain-processed allografts achieved superior outcomes in treating diabetic foot ulcers (DFUs), with the BR-AC arm being almost twice as likely to achieve lasting wound closure compared to standard care [3][4] - The trial utilized advanced statistical methods, including Bayesian regression, to quantify treatment effects and improve understanding of wound healing across diverse patient populations [3][4] Group 3: Benefits of Bayesian Methodologies - Bayesian methodologies are particularly beneficial in regenerative medicine and wound care, where datasets are often smaller and variability is high, allowing for more informed clinical decision-making [5] - The incorporation of prior knowledge with new data through Bayesian frameworks supports probabilistic interpretation, enhancing the relevance of clinical insights for healthcare stakeholders [5] Group 4: Commitment to Innovation - BioStem is dedicated to advancing evidence-based innovation in wound care through rigorous clinical research and real-world data analysis, supported by proprietary technologies like BioRetain and CryoTek [7] - The company aims to optimize the preservation of the natural structural and biological integrity of amniotic tissue, which is crucial for effective regenerative therapies [7][9]

Core Insights - BioTissue Holdings, Inc. has completed the sale of its non-ocular Surgical and Wound Care business to BioStem Technologies, Inc., allowing BioTissue to focus on ocular market leadership and innovation in eye care solutions [1][2][3] Company Overview - BioTissue specializes in utilizing human birth tissue for regenerative healing, particularly in treating acute and chronic ocular surface conditions [4] - The company has developed a portfolio of cryopreserved amniotic membrane products using proprietary CryoTek® technology, which preserves the tissue's structural and functional integrity [4] - BioTissue has conducted over 1 million human procedures with its products and has over 420 peer-reviewed publications supporting its technology [4] Strategic Focus - Following the divestiture, BioTissue will concentrate on advancing interventional therapies for ocular conditions, including products like Prokera, CAM360 AmnioGraft, and AmnioGuard [2][3] - The company aims to prioritize product innovation, professional education, and comprehensive customer support within the eye care market [2] Partnership with BioStem - BioStem Technologies will acquire exclusive rights to BioTissue's Neox and Clarix product lines, integrating BioTissue's surgical sales team into its commercial organization [2][3] - BioStem's CEO highlighted the complementary strengths of BioTissue's portfolio to their existing business, indicating a strong potential for growth and improved patient outcomes [3]

Core Viewpoint - BioStem Technologies, Inc. has acquired the surgical and wound care business of BioTissue Holdings Inc. for approximately $15 million, enhancing its commercial organization and expanding its market reach in advanced wound care [1][4][5]. Group 1: Acquisition Details - BioStem has closed a definitive asset purchase agreement with BioTissue, acquiring its full portfolio of surgical and wound care assets, including the Neox and Clarix product lines [2][3]. - The acquisition includes a nationwide network of sales representatives and independent agents, along with key GPO contracts, significantly expanding BioStem's commercial capabilities [2][3]. - The total upfront cash payment for the acquisition is approximately $15 million, with potential additional payments of up to $25 million based on regulatory and commercial milestones [4][5]. Group 2: Financial Impact - The acquired assets generated approximately $29 million in sales in 2025 and are expected to contribute positively to BioStem's EBITDA in 2026 [5]. - Post-acquisition, BioStem's cash and restricted cash balance is approximately $16 million [5]. Group 3: Leadership Changes - Barry Hassett has been promoted to Chief Commercial Officer to lead the newly combined commercial team, bringing over 25 years of industry experience [6].

Core Viewpoint - BioStem Technologies, Inc. has commented on the withdrawal of all seven Local Coverage Determinations (LCDs) by the Centers for Medicare & Medicaid Services (CMS) for skin substitute grafts and cellular products for treating diabetic foot ulcers and venous leg ulcers, effective January 1, 2026, indicating that this will not impact patient access to their technology [1][2]. Company Overview - BioStem Technologies is a MedTech company focused on developing, manufacturing, and commercializing placental-derived products for advanced wound care [1]. - The company utilizes its proprietary BioRetain processing method, which is designed to maintain growth factors and preserve tissue structure [2]. - BioStem's quality management system has been accredited by the American Association of Tissue Banks (AATB) and complies with current Good Tissue Practices (cGTP) and Good Manufacturing Processes (cGMP) [2]. Market and Innovation - The company emphasizes the importance of high-quality clinical evidence for long-term adoption and value creation, committing to an evidence-based strategy [2]. - BioStem plans to continue investing in expanding its clinical data foundation to demonstrate the differentiated performance of its proprietary technology compared to alternatives [2]. Product Portfolio - BioStem's product portfolio includes brands such as AmnioWrap2™, VENDAJE, and American Amnion™, all processed at their FDA registered and AATB accredited site in Pompano Beach, Florida [2].

Core Viewpoint - BioStem Technologies, Inc. has received a 12-month status quo designation for its products, ensuring continued reimbursement eligibility for diabetic foot ulcers (DFU) and venous leg ulcers (VLU) through 2026, while coverage for pressure ulcers remains unaffected by recent CMS updates [1][2][3][4]. Group 1: Reimbursement and Coverage - The Centers for Medicare & Medicaid Services (CMS) has categorized products into three groups: Covered, Non-Covered, and 12-Month Status Quo, allowing products in the Status Quo category to remain eligible for reimbursement as long as they meet the "reasonable and necessary" standard [2]. - The final Local Coverage Determinations (LCDs) specifically apply to DFU and VLU, not affecting payments for other wound types, thus maintaining consistent care for non-DFU/VLU patients [3]. - BioStem's largest reimbursement segment, related to pressure ulcers, remains unchanged, allowing continued use of its products without coverage interruption [3]. Group 2: Company Strategy and Future Plans - The CEO of BioStem expressed confidence that the status quo designation will ensure uninterrupted payment for its products in DFU and VLU applications throughout 2026, while also preserving access and revenue stability for the company's core pressure ulcer business [4]. - BioStem has submitted new clinical and scientific data to CMS, demonstrating the superiority of its products over standard care, and plans to engage in further discussions with CMS regarding its clinical trial findings [4]. - The company aims to transition its products from Status Quo to Covered status during the 2027 reconsideration cycle, emphasizing its commitment to generating clinical evidence and ensuring access to its placental allografts [4].

Core Insights - BioStem Technologies, Inc. has announced the inclusion of its products VENDAJE and VENDAJE AC in Florida Medicaid's list of covered skin substitutes, marking a significant milestone in its national reimbursement strategy [1][2][3] Group 1: Company Developments - The addition of Florida Medicaid coverage enhances BioStem's mission to provide high-quality wound care, significantly increasing its addressable patient base in one of the largest Medicaid markets in the U.S. [3] - BioStem's advanced wound care market is estimated to exceed $11 billion annually in the U.S., with over 70 million Americans enrolled in Medicaid, including approximately 7 million aged 65 and older [3] Group 2: Product Information - VENDAJE and VENDAJE AC are placental-derived, minimally manipulated dehydrated tissue allografts designed for soft tissue wound protection, utilizing the proprietary BioREtain technology to optimize the retention of extracellular matrix scaffolding [5][6] Group 3: Distribution Strategy - BioStem is actively seeking qualified regional distributors and wound care organizations to represent the VENDAJE portfolio in Florida and other covered states [4]